A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

September 30, 2004

Conditions
Schizophrenia
Interventions
DRUG

Clozapine

Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks

DRUG

Ziprasidone

Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks

Trial Locations (22)

10126

Pfizer Investigational Site, Torino

25018

Pfizer Investigational Site, Montichiari (brescia)

25100

Pfizer Investigational Site, Brescia

34126

Pfizer Investigational Site, Trieste

36061

Pfizer Investigational Site, Bassano del Grappa

37126

Pfizer Investigational Site, Verona

43100

Pfizer Investigational Site, Parma

50134

Pfizer Investigational Site, Florence

53100

Pfizer Investigational Site, Siena

66016

Pfizer Investigational Site, Guardiagrele (CH)

70124

Pfizer Investigational Site, Bari

80131

Pfizer Investigational Site, Napoli

89100

Pfizer Investigational Site, Reggio Calabria

95123

Pfizer Investigational Site, Catania

98100

Pfizer Investigational Site, Messina

06012

Pfizer Investigational Site, Città di Castello

09045

Pfizer Investigational Site, Cagliari

09124

Pfizer Investigational Site, Cagliari

00135

Pfizer Investigational Site, Roma

00137

Pfizer Investigational Site, Roma

07100

Pfizer Investigational Site, Sassari

Unknown

Pfizer Investigational Site

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00649844 - A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs | Biotech Hunter | Biotech Hunter